Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental ...

Biotechnology-driven Future Society has collected microbes from cloud environments, sequenced them and analysed the scent ...

Nextstar Energy Inc. was registered this past week by Hunseong Lee, the company’s CEO, to lobby. A battery manufacturer whose ...

Using proprietary real-world patient data and an early validated drug candidate, Analgesia.ai is building an AI-powered ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...

In the current geopolitical and capital-market uncertainty, biotechs that have not mastered the basics are the ones ...